Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marcel Costa-García
Observed names:
Costa-Garcia, Marcel,
M Costa-Garcia,
M. Costa-García,
Marcel Costa,
Marcel Costa-Garcia
Institutions:
Institut d'Investigació Biomédica de Bellvitge,
Institut Català d'Oncologia
Observed institutions:
Universitat Pompeu Fabra,
Institut d'Investigació Biomédica de Bellvitge,
Institut Català d'Oncologia,
Hospital Del Mar,
Municipal Institute for Medical Research,
Hospital del Mar Research Institute,
ProCure (United States)
show all 7
ORCID:
0000-0002-1930-6048
Observed ORCID:
0000-0002-1930-6048
OpenAlex ID:
A5032750178
NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival
2019
·
Aura Muntasell
, Federico Rojo
, et al.
·
Clinical Cancer Research
·
137
Antibody-Mediated Response of NKG2Cbright NK Cells against Human Cytomegalovirus
2015
·
Marcel Costa-Garcia
, Andrea Vera
, et al.
·
The Journal of Immunology
·
132
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
2022
·
Rocio Garcia-Carbonero
, Miriam Bazan-Peregrino
, et al.
·
Journal for ImmunoTherapy of Cancer
·
109
PDF
Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes
2019
·
Marcel Costa-García
, Michelle Ataya
, et al.
·
Frontiers in Immunology
·
72
PDF
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
2023
·
J.M. Piulats
, C. Watkins
, et al.
·
Annals of Oncology
·
53
PDF
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
2024
·
Sara Santana-Hernández
, Jesús Suarez-Olmos
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
49
PDF
High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer
2019
·
Aura Muntasell
, Sònia Servitja
, et al.
·
Cancer Immunology Research
·
42
CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
2021
·
Mariona Cabo
, Sara Santana-Hernández
, et al.
·
Cancer Immunology Research
·
37
PDF
Pretransplant adaptive NKG2C+ NK cells protect against cytomegalovirus infection in kidney transplant recipients
2019
·
Michelle Ataya
, Dolores Redondo-Pachón
, et al.
·
American Journal of Transplantation
·
37
Elusive Role of the CD94/NKG2C NK Cell Receptor in the Response to Cytomegalovirus: Novel Experimental Observations in a Reporter Cell System
2017
·
Aldi Pupuleku
, Marcel Costa-García
, et al.
·
Frontiers in Immunology
·
31
PDF
Priming of NK Cell Anti-Viral Effector Mechanisms by Direct Recognition of Human Cytomegalovirus
2013
·
Aura Muntasell
, Marcel Costa-Garcia
, et al.
·
Frontiers in Immunology
·
31
PDF
Adaptive Features of Natural Killer Cells in Multiple Sclerosis
2019
·
Antía Moreira
, Elisenda Alari-Pahissa
, et al.
·
Frontiers in Immunology
·
30
PDF
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
·
Clinical Cancer Research
·
23
1,4-dihydroxy quininib activates ferroptosis pathways in metastatic uveal melanoma and reveals a novel prognostic biomarker signature
2024
·
Valentina Tonelotto
, Marcel Costa-Garcia
, et al.
·
Cell Death Discovery
·
16
Development of the adaptive NK cell response to human cytomegalovirus in the context of aging
2016
·
Miguel López-Botet
, Aura Muntasell
, et al.
·
Mechanisms of Ageing and Development
·
16
Ergolide mediates anti-cancer effects on metastatic uveal melanoma cells and modulates their cellular and extracellular vesicle proteomes
2023
·
Husvinee Sundaramurthi
, Valentina Tonelotto
, et al.
·
Open Research Europe
·
13
Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patients
2023
·
Sandra García-Mulero
, Roberto Fornelino
, et al.
·
OncoImmunology
·
12
PDF
Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors
2024
·
M Costa-Garcia
, JJ Rojas
, et al.
·
Cancer Immunology Immunotherapy
·
5
PDF
Optimized protocol for culturing menstrual blood-derived MSCs for combination with oncolytic adenoviruses in cancer treatment
2024
·
Marcel Costa-Garcia
, Laura Moya-Borrego
, et al.
·
Molecular Therapy Oncology
·
4
4P T cell phenotype and repertoire are modulated by neoadjuvant chemotherapy (NACT) in high-grade serous ovarian cancer (HGSOC)
2025
·
J.A. Marin Jimenez
, D. Barras
, et al.
·
ESMO Open
·
1
PDF
Ergolide Mediates Anti-Cancer Effects on Metastatic Uveal Melanoma Cells and Modulates their Cellular and Extracellular Vesicle proteomes
2023
·
Sundaramurthi, Husvinee
, Tonelotto, Valentina
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
·
1
Abstract B003: Enhancing anti-tumoral reactivity with iHPK1 in liver metastasis to revitalize TIL product for therapy
2025
·
Luis P. Del Carpio Huerta
, Ainhoa Muñoz
, et al.
·
Cancer Immunology Research
Supplementary Table S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Show more works
View as search
Works count:
52
Citation count:
851
H-index:
15
I10-index:
17
Year
Topic
Type